These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38813103)

  • 1. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Liu Y; Shao R
    Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
    He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
    PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
    Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
    Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
    Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
    Shao T; Zhao M; Tang W
    Front Oncol; 2022; 12():953671. PubMed ID: 36561521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Shi F; He Z; Su H; Wang L; Han S
    Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
    Li W; Wan L; Zhang J
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):293-301. PubMed ID: 38923910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Luo X; Zhou Z; Zeng X; Liu Q
    Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.
    Pei Z; Xiao N; Yang P
    Front Pharmacol; 2023; 14():1265784. PubMed ID: 37964872
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
    Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
    Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
    Liu S; Jiang N; Dou L; Li S
    Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
    Zheng Z; Chen H; Cai H; Zhu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
    Zhao M; Shao T; Chi Z; Tang W
    Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.